Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02903381 · OUTCOME

Progression Free Survival (PFS) Probability at 2-years

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma · Source last updated 2023-06-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
probability
Interval / dispersion
90% Confidence Interval
Time frame
Baseline to disease progression or death from any cause, censored at date last known progression free for those who have not progressed or died, up to 24 months post initiation of therapy.

What was measured

Kaplan-Meier method, percent of patients alive and progression-free at 2-years

Groups in this outcome

Nivolumab, Lenalidomide, Dexamethasone

* A treatment cycle is defined as 28 consecutive days. * Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months. Nivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and Lenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12 Dexamethasone: Oral, Days 1, 8, 15 of cycle 1-6

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Nivolumab, Lenalidomide, Dexamethasone8

Reported measurements

Source class 1
Values in probability · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Nivolumab, Lenalidomide, Dexamethasone0.75Not reported0.541.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.54
        upper Limit
        1.0
        value
        0.75
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Kaplan-Meier method, percent of patients alive and progression-free at 2-years
dispersion Type
90% Confidence Interval
groups
  1. description
    * A treatment cycle is defined as 28 consecutive days. * Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months. Nivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and Lenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12 Dexamethasone: Oral, Days 1, 8, 15 of cycle 1-6
    id
    OG000
    title
    Nivolumab, Lenalidomide, Dexamethasone
param Type
NUMBER
reporting Status
POSTED
time Frame
Baseline to disease progression or death from any cause, censored at date last known progression free for those who have not progressed or died, up to 24 months post initiation of therapy.
title
Progression Free Survival (PFS) Probability at 2-years
type
SECONDARY
unit Of Measure
probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice